HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer (Q30837184)

10 August 2017

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer (English)

1 reference

10 August 2017

1

Eric Van Cutsem

0 references

Yung-Jue Bang

2

object named as

Yung-Jue Bang

1 reference

10 August 2017

Feng Feng-Yi

3

1 reference

10 August 2017

Jian M Xu

4

1 reference

10 August 2017

Keun-Wook Lee

5

1 reference

10 August 2017

Shun-Chang Jiao

6

1 reference

10 August 2017

Jorge León Chong

7

1 reference

10 August 2017

Roberto I López-Sanchez

8

1 reference

10 August 2017

Timothy Price

9

1 reference

10 August 2017

Oleg Gladkov

10

1 reference

10 August 2017

Oliver Stoss

11

1 reference

10 August 2017

Julie Hill

12

1 reference

10 August 2017

Vivian Ng

13

1 reference

10 August 2017

Michaela Lehle

14

1 reference

10 August 2017

Marlene Thomas

15

1 reference

10 August 2017

Astrid Kiermaier

16

1 reference

10 August 2017

Josef Rüschoff

17

1 reference

10 August 2017

20 July 2014

1 reference

10 August 2017

1 reference

10 August 2017

18

1 reference

10 August 2017

3

1 reference

10 August 2017

476-484

1 reference

Creative Commons Attribution 4.0 International

10 August 2017

start time

20 July 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Adenocarcinoma of the GEJ: gastric or oesophageal cancer?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

HER2 testing in gastric cancer: a practical approach

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Molecular Classification of Gastric Cancer: A New Paradigm

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511072

Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma

25 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25038874

12 December 2020

inferred from PubMed ID database lookup

Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25038874

12 December 2020

inferred from PubMed ID database lookup

Prognostic factors in gastric cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25038874

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10120-014-0402-Y

1 reference

Dimensions Publication ID

10 August 2017

1047548049

0 references

Fatcat ID

release_eiua34nvg5fubawyj3af24vky4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/eiua34nvg5fubawyj3af24vky4

24 November 2022

mapped directly with Wikidata item

1 reference

10 August 2017

PubMed publication ID

25038874

1 reference